Background {#Sec1}
==========

Ovarian cancer has the highest mortality among gynecological cancers and is associated with 4.2 % of all cancer-related deaths in women \[[@CR1]\]. The four major histological subtypes include serous adenocarcinoma (SAC), clear cell carcinoma (CCC), endometrioid adenocarcinoma, and mucinous adenocarcinoma. Although the underlying reason remains unknown, CCC prevalence varies with race, with an estimated prevalence of 1--12 % in Europe and North America \[[@CR2]\] and 15--25 % in Japan. Thus, CCC is the second most common histological subtype of epithelial ovarian cancer (EOC) in Japan \[[@CR2], [@CR3]\]. Over the past decade, advances in surgical and chemotherapeutic management have improved progression-free survival (PFS) and overall survival (OS) rates.

Platinum and taxane agents are typically included in standard intravenous regimens administered to women requiring first-line chemotherapy for ovarian cancer \[[@CR4]\], and high response rates (60--80 %) have been shown with them. Although these chemotherapies have improved PFS and OS in ovarian cancer, some histological subtypes have shown low response rates. Moreover, standard chemotherapy using paclitaxel and carboplatin has exhibited an approximately 70 % response rate in the treatment of SAC, the most common ovarian carcinoma subtype, but only 18--56 % for CCC \[[@CR3], [@CR5], [@CR6]\].

CCC tumors tend to present at earlier stages, with 47--81 % diagnosed at stage I or II, and showing a similar prognosis to SACs \[[@CR7]\]. However, advanced CCC (i.e., FIGO stage III or IV) has a poorer prognosis, and available treatments are less effective owing to its resistance toward chemotherapeutic agents. Accordingly, in comparison with advanced SAC, the clinical prognosis for advanced CCC is remarkably inferior, primarily because of its chemoresistant behavior \[[@CR8]--[@CR10]\].

As an alternative to platinum drugs, irinotecan has been shown to be a promising candidate for the treatment of CCC in retrospective studies \[[@CR11], [@CR12]\] and a randomized phase II trial \[[@CR13]\]. However, the combination therapy of irinotecan plus cisplatin (CPT-P) failed to show efficacy. A recent randomized phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) was conducted by the Japanese Gynecologic Oncology Group (JGOG 3017). This trial was the first CCC-specific international clinical trial. With a 44.3-month median follow-up, the 2-year PFS was 73.0 % in the CPT-P arm and 77.6 % in the TC arm. The 2-year OS was 85.5 % in the CPT-P arm and 87.4 % in the TC arm. That is, there were no significant changes in PFS and OS at 2 years between the two groups.

Based on these findings, CCC is considered a highly malignant and chemoresistant type of ovarian cancer, and conventional chemotherapy is not regarded as an effective treatment. In this review, we focus on potential therapeutic molecular targets and discuss prospective treatments.

Review {#Sec2}
======

Molecular mechanisms of platinum resistance in ovarian CCC {#Sec3}
----------------------------------------------------------

Several mechanisms involved in platinum resistance have been proposed, including pre-, on-, post-, and off-target mechanisms as well as the speed of cell proliferation \[[@CR14]\]. Our consideration of platinum resistance in CCC is shown in Fig. [1](#Fig1){ref-type="fig"} and summarized in Table [1](#Tab1){ref-type="table"} \[[@CR15]--[@CR53]\].Fig. 1Mechanisms of platinum resistance in CCC. At present, five mechanisms of platinum resistance have been characterized in CCC, including pre-, on-, post-, and off-target mechanisms, and slow cell proliferation. *ABCC3* ATP-binding cassette, subfamily C, member 3, *ERCC1* excision repair cross-complementing rodent repair deficiency complementation group 1, *EGFR* epidermal growth factor receptor, *HER2* human epidermal growth factor receptor 2Table 1Summary of potential targets for platinum resistance in CCCCategory of platinum resistanceTarget molecule *Pre targetABCC3*FunctionABCC3 is expressed in the liver, small intestine, and colon. ABCC3 belongs to the ABCC subfamily, consisting of 13 members in mammals that are divided into three classes: multi-drug resistance proteins, sulfonylurea receptors, and the cystic fibrosis transmembrane conductance regulator \[[@CR15]\]. ABCC3 transports monovalent bile salts (i.e., taurocholate and glycocholate) and sulfated bile salts(i.e., taurochenodeoxycholate-3-sulfate, taurolithocholate-3-sulfate) \[[@CR15]\]In cancer tissuesOverexpression of ABCC3, which transports chemotherapeutic agents, has been associated with paclitaxel resistance in breast cancer cell lines \[[@CR16], [@CR17]\] and cisplatin resistance in ovarian cancer cell lines \[[@CR18]\]In CCCOne study reported that ABCC3 mRNA expression in CCC was significantly higher than that in SAC \[[@CR19]\]. However, no study to date has investigated potential mechanisms of platinum resistance in CCC*Annexin A4*FunctionAnnexin A4 (Anx A4) is a member of the Ca^2+^-regulated and phospholipid-binding annexin protein superfamily, and is believed to be involved in exocytosis and regulation of epithelial Cl^−^ secretion \[[@CR20]\]In cancer tissuesStudies indicate that Anx A4 up-regulation promotes tumor progression and chemoresistance in colorectal cancer, esophageal squamous cell carcinoma, endometrial carcinoma, gastric cancer, chemoresistant lung cancer, malignant mesothelioma, renal cell carcinoma, ovarian clear cell carcinoma (CCC), cholangiocarcinoma, hepatocellular carcinoma, breast cancer, and laryngeal cancer \[[@CR21]\]In CCCEnhanced Anx A4 expression was identified in both clinical samples and ovarian CCC cell lines by 2-D differential gel electrophoresis (2D-DIGE) and mass spectrometry \[[@CR22]\]. Anx A4 confers chemoresistance to ovarian CCC cell lines \[[@CR23]\]. Proposed mechanisms of annexin-A4-mediated chemoresistance include (1) reduction of intracellular platinum content and (2) enhancement of NF-kB transcriptional activity via interaction of Anx A4 with NF-kB. Anx A4 is one of the most investigated platinum resistance factors in CCC \[[@CR20], [@CR22]--[@CR25]\]*Glutathione peroxidase 3 (GPx3)*FunctionThe Glutathione Peroxidase (GPx) family is composed of eight members (GPx1--GPx8) that play roles in removing redundant reactive oxygen species (ROS) to reduce oxidative damage to host cells. The GPx3 gene is located on chromosome 5q23 and encodes a protein that accounts for nearly all GPx activities in plasma \[[@CR26]\]In cancer tissuesGPx3 expression has been reported in hepatocellular carcinoma, gastric cancer, acute myeloid leukemia, and clear cell renal cell carcinoma \[[@CR27]\]. One study reported a correlation between GPx3 methylation and chemoresistance in head and neck cancer (HNC), which may serve as a potential prognostic indicator of HNC after cisplatin-based chemotherapy \[[@CR28]\]In CCCOnly one study to date has investigated the role of GPx3 in CCC \[[@CR29]\]. The GPx3 gene was found to be highly expressed in CCC by DNA microarray analysis. GPx3 suppression by RNA interference increased cisplatin sensitivity by approximately 4-fold in CCC cell lines. Since GPx3 suppression increased cisplatin sensitivity of CCC cells, GPx3 may be a candidate gene associated with platinum resistance in CCC \[[@CR29]\] *On targetERCC1 (NER system)*FunctionERCC1 was the first human DNA repair gene identified by molecular cloning. The ERCC1 and ERCC4 genes encode the two subunits of ERCC1-XPF nuclease, an enzyme that plays an important role in DNA repair and maintenance of genomic stability \[[@CR30]\]. ERCC1-XPF nuclease nicks DNA specifically at junctions between double-stranded and single-stranded DNA, when the single-strand is oriented in a 5′ to 3′ direction away from a junction. ERCC1-XPF is a core component of nucleotide excision repair and plays a role in interstrand crosslink repair, some pathways of double-strand break repair by homologous recombination and end-joining, as a backup enzyme in base excision repair, and in telomere length regulation \[[@CR30]\]In cancer tissuesERCC1 is perhaps one of the most important components of the NER pathway and a key determinant of cisplatin resistance. When we consider the role that it plays in other DNA repair processes, such as recombination, it is observed that in recent years, ERCC1 has become one of the most studied prognostic factors of platinum therapy \[[@CR31]\]. ERCC1 is reportedly a platinum-resistance factor in cancers of the ovary, lung, colorectum, and stomach \[[@CR31]--[@CR34]\]In CCCAlthough a detailed investigation was not conducted, one study detected higher ERCC1 mRNA levels in CCC specimens than other histological types of epithelial ovarian cancer \[[@CR35]\]. Because ERCC1 was found to play an important role in platinum resistance in other cancers, further investigations into the role of ERCC1 in CCC are expected *Post targetGalectin 3*Function:The galectins comprise a family of 14 members of β-galactoside-binding proteins, which are characterized by an affinity for β-galactosides and a conserved sequence in the carbohydrate recognition domain that binds to the carbohydrate portion of cell surface glycoproteins or glycolipids \[[@CR36]\]. Galectin 3 is widely expressed in epithelial and immune cells in the gastric mucosa, colon mucosa, mammary epithelium, and prostate epithelium, as well as monocytes and macrophages. The Galectin 3 gene encodes a 31-kDa multifunctional oncogenic protein that plays a role in the regulation of cell growth, adhesion, proliferation, and apoptosis, as well as angiogenesis \[[@CR36]\]In cancer tissuesGalectin 3 has been implicated in many aspects of cancer progression, such as tumor cell adhesion, proliferation, differentiation, and metastasis \[[@CR37]\], and is associated with platinum resistance in cancers of the ovary, pancreas, and prostate \[[@CR38]--[@CR41]\]. Galectin 3 has also been shown to protect cells against chemotherapy-induced apoptosis and has been implicated in the regulation of universal apoptosis commitment \[[@CR37]\]In CCCOnly one study to date has investigated the role of Galectin 3 in CCC \[[@CR42]\]. Cisplatin-induced apoptosis was increased after Galectin 3 knock-down. Immunohistochemical staining showed that Galectin 3 expression in CCC was significantly more frequent than in SAC. Because p27 protein expression was decreased after Galectin 3 knock-down, the author concluded that Galectin 3 expression in CCC might contribute to decreased cell proliferation and lead to cisplatin resistance \[[@CR42]\] *Off targetEGFR*FunctionEpidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that belongs to the receptor tyrosine kinase family of growth factor receptors and participates in important physiological process, such as cell survival, proliferation, and motility \[[@CR43]\]In cancer tissuesEGFR overexpression has been associated with advanced disease and poor survival of patients with cancers of the breast, lung, liver, prostate, and ovary \[[@CR43]\]. Alterations to EGFR coding sequences are also frequently found in human cancers. Most variants with deletions in the extracellular domain are correlated with poor survival. In general these variants are constitutively active and confer a growth advantage and increased malignant potential to tumor cells \[[@CR43], [@CR44]\]. Overexpression or mutated EGFR is reportedly associated with platinum resistance in lung and ovarian cancer \[[@CR14], [@CR43], [@CR45]\]In CCCA previous study reported EGFR overexpression in approximately 60 % CCC specimens and selective inhibition of the EGFR decreased growth and invasion of ovarian CCC cells \[[@CR46]\]. Another study reported that EGFR inhibition increased cisplatin efficacy in ovarian CCC cells \[[@CR47]\]. Together, the results of these studies suggest that EGFR is an important therapeutic target to improve platinum-resistance in CCC*HER2*FunctionHER2 (ErbB2) is a type I transmembrane protein that belongs to the EGFR family, which includes EGFR, ErbB1, HER1, HER3, and −4 (ErbB3 and −4) \[[@CR48]\]. Normal HER2 function is associated with cellular differentiation, growth, development, and apoptosis via activation of tyrosine kinase activity through dimerization of HER2, with itself or other members of the EGFR family \[[@CR48]\]In cancer tissuesAmplification or overexpression of HER2 occurs in approximately 15--30 % of breast cancers and 10--30 % of gastric/gastroesophageal cancers, and serves as a prognostic and predictive biomarker. HER2 overexpression has also been identified in cancers of the ovary, endometrium, bladder, lung, colon, and head/neck. The introduction of HER2-directed therapies has dramatically influenced the outcome of patients with HER2-positive breast and gastric/gastroesophageal cancers; however, the results have proved disappointing in other HER2-overexpressing cancers \[[@CR49]\]. The association between HER2 and platinum resistance in breast cancer cells \[[@CR50]\] and the data of a systematic review suggest that triple-negative breast cancer have increased sensitivity to platinum-based chemotherapy \[[@CR51]\]In CCCAmplification and overexpression of HER2 have been described in 14--42.9 % of Ovarian CCC cases \[[@CR52], [@CR53]\]. However, no report to date has investigated the association between HER2 and mechanisms of platinum resistance in CCC*ABCC3* ATP-binding cassette, subfamily C, member 3, *ABC* ATP-binding cassette, *CCC* clear cell carcinoma, *SAC* serous adenocarcinoma, *GPx* glutathione peroxidase, *ERCC1* excision repair cross-complementing rodent repair deficiency complementation group 1, *NER* nucleotide excision repair, *EGFR* epidermal growth factor receptor, *HER2* human epidermal growth factor receptor 2. We summarized the factors of platinum resistance in CCC. We introduced the factors of normal function, function in cancer, and function in CCC

Pre-target mechanisms include at least two mechanisms using which cancer cells elude the cytotoxic potential of cisplatin before binding to cytoplasmic targets and DNA: (1) a reduced intracellular accumulation of cisplatin and (2) an increased sequestration of cisplatin by glutathione, metallothioneins, and other cytoplasmic scavengers with nucleophilic properties \[[@CR14]\].

Previous studies have shown that the expression of the *ABCC3* gene is significantly greater in CCC than in SAC. Increased expression of *ABCC3* may, at least in part, be associated with the chemoresistant phenotype of CCC \[[@CR19]\]. Moreover, *AnxA4* overexpression reportedly stimulates efflux of platinum drugs and induces platinum resistance \[[@CR20], [@CR54], [@CR55]\]. Increased sequestration of platinum agents in CCC has also been reported, with significantly increased glutathione concentrations in cell lines after cisplatin exposure \[[@CR56]\]. Furthermore, a study of gene expression showed that glutathione peroxidase 3, glutaredoxin, and superoxide dismutase 2 were highly expressed in CCC tumors and that elevated levels of these proteins may render the tumors more resistant to chemotherapy \[[@CR57]\].

The on-target mechanism involves repair of adducts at an increased pace and/or the ability to tolerate unrepaired DNA lesions, reflecting activity of a particular class of DNA polymerases \[[@CR14]\]. The majority of cisplatin lesions are removed from DNA by the nucleotide excision repair (NER) system \[[@CR14], [@CR58]\]. One study revealed higher mRNA expression of *ERCC1* and *XPB* genes in CCC. These genes are involved in the NER pathway of EOC and are more prevalent in CCC than in other histological subtypes of EOC \[[@CR35]\]. This phenomenon may be related to de novo drug resistance against chemotherapeutic agents in CCC.

Post-target resistance to cisplatin may follow several alterations, including defects in signal transduction pathways and issues with cell death machinery \[[@CR14]\]. In this mechanism, galectin-3 is associated with CCC platinum resistance, and suppression of galectin-3 reportedly leads to *cis*-diamminedichloroplatinum-induced apoptosis via decreases in p27 protein expression \[[@CR42]\].

Regarding the off-target mechanism, accumulating evidence suggests that the cisplatin-resistant phenotype can also be maintained by alterations in signaling pathways that are not directly engaged by cisplatin, and yet, these compensate for cisplatin-induced lethal signals \[[@CR14]\]. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are cell-surface receptor tyrosine kinases that are capable of activating both mitogen-activated protein kinase and phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathways. This leads to phosphorylation of BAD and Bcl-2 and results in the inhibition of chemotherapy-induced apoptosis. An immunohistochemical study reported that the expression of EGFR was detected in 61 % of CCC tumors \[[@CR46]\]. Furthermore, HER2 was reportedly overexpressed in CCC in comparison with other major histological subtypes of EOC. In ovarian cancer, the HER2 protein was overexpressed as a consequence of gene amplification in 20--25 % of cases and predicted poor prognosis \[[@CR59], [@CR60]\]. Moreover, HER2 was overexpressed in 42.9 % of CCC cases, as investigated using immunohistochemistry (IHC) \[[@CR61]\].

Slow cell proliferation is also associated with platinum resistance because cytotoxic drugs primarily target proliferating cells \[[@CR5]\], and doubling times for CCC cells were significantly longer than those for SAC cells (61.4 vs. 29.8 h) \[[@CR5]\].

Determining the mechanisms underlying platinum resistance in CCC is important, because no novel drugs have yet proven effective for CCC treatment. Our review revealed that annexin A4 (AnxA4) is one of the most well-investigated platinum resistance factors in CCC \[[@CR20], [@CR22]--[@CR25]\]. A recent study showed that *AnxA4* knockout improved platinum resistance of CCC in vitro and in vivo \[[@CR56]\], and the functional site of AnxA4 that is responsible for conferring platinum resistance has been identified. If an AnxA4 blockade drug was developed, its use in combination with platinum drugs could have therapeutic activity against CCC.

Characteristics of ovarian CCC {#Sec4}
------------------------------

The molecular features of CCC are summarized in Table [2](#Tab2){ref-type="table"} \[[@CR22], [@CR24], [@CR46], [@CR52], [@CR53], [@CR61]--[@CR72]\]. One major distinguishing characteristic is its higher incidence among Asian populations, particularly among Japanese women \[[@CR2], [@CR3], [@CR56]\]. The reason for this is unknown, although CCC has been associated with endometriosis and endometriosis-associated ovarian cancers in 22--70 % of younger female patients \[[@CR73]\]. Previous studies showed that ovarian endometrioma increases the risk for ovarian cancer, and 0.72 % of all cases of ovarian endometrioma later develop neoplasms \[[@CR74]\].Table 2Characteristics of ovarian clear cell carcinomas and potential molecular targetsClinical featuresMutated genes and overexpressed proteinsReferenceHigher incidence among Asian women, particularly Japanese womenARID1A is mutated in 46 % of CCC patients (loss of function)\[[@CR62], [@CR85]\]Clear cell carcinoma has a strong association with endometriosisPIK3CA is mutated in 33 % of CCC patients (activation mutation)\[[@CR53]\]Slow tumor growth, facilitating early detectionAnnexin A4 is expressed in almost all CCC patients\[[@CR20], [@CR22]\]Strong resistance to platinum-based chemotherapymTOR is overexpressed in 80 % of CCC patients\[[@CR63]\]Promising regimens with favorable and stable response for ovarian clear cell carcinoma have remained elusiveHNF-1β is expressed in almost all CCC patients\[[@CR52], [@CR64], [@CR71]--[@CR73]\]Low frequency of BRCA1/2 mutationsZNF217 is overexpressed in 20 % of CCC patients\[[@CR65]\]Low frequency of p53 mutations (15 %)VEGF is strongly expressed in both early and advanced stages of CCC\[[@CR66]\]EGFR is overexpressed in 60 % of CCC patients\[[@CR59]\]MET is overexpressed in approximately 20 % of CCC patients\[[@CR85]\]HER2 is overexpressed in 14--42.9 % of CCC patients\[[@CR52], [@CR53]\]PPMID expression is observed in 10 % of CCC patients\[[@CR68]\]PPP2R1A is overexpressed in 7 % of CCC patients\[[@CR52]\]KRAS is overexpressed in 5 % of CCC patients\[[@CR52]\]*ARID1A* AT-rich interactive domain 1A (SWI-like) gene, *BRCA 1/2* breast cancer susceptibility gene 1/2, *EGFR* epidermal growth factor receptor, *HER2* human epidermal growth factor receptor 2, *HNF-1β* hepatocyte nuclear factor 1β, *mTOR* mammalian target of rapamycin, *PIK3CA* phosphoinositide 3-kinase catalytic-α, *PPMID* protein phosphatase magnesium-dependent, *PP2R1A* protein phosphatase 2, regulatory subunit A, *VEGF* vascular endothelial growth factor, *ZNF217* zinc finger protein 217

CCC tends to present at significantly earlier stages than other ovarian cancers, possibly owing to slow tumor growth and frequent presentation of tumors as large pelvic masses \[[@CR75]\], and the proportion of stage I/II tumors ranges from 59 to 71 % \[[@CR3]\].

Unlike high-grade serous EOCs, CCCs usually display a wild-type p53 and have a lower frequency of *BRCA1* and *BRCA2* mutations \[[@CR2], [@CR76], [@CR77]\]. Significant differences were reported in the distribution of mutations among histological subtypes, and *TP53* mutations were reportedly present in 67 and 21 % of cases with serous and nonserous cancers, respectively \[[@CR76]\]. Similar studies report much lower frequencies of p53 mutations (approximately 15 %) in CCC than in other EOC types \[[@CR2]\]. Similarly, Alsop et al. reported that the frequency of *BRCA1* and *BRCA2* mutations of CCC was 6.3 and 0 %, respectively \[[@CR77]\]. However, other recent studies have revealed that several genes/proteins are mutated and/or overexpressed in CCC, and that these proteins may serve as therapeutic targets for CCC (Table [2](#Tab2){ref-type="table"}) \[[@CR22], [@CR24], [@CR46], [@CR52], [@CR53], [@CR61]--[@CR72]\].

Novel therapeutic modalities for CCC {#Sec5}
------------------------------------

Paclitaxel plus carboplatin combination therapy is currently the primary treatment strategy in postoperative chemotherapy. However, advanced-stage patients eventually relapse after adjuvant therapy and have a high risk of recurrence \[[@CR3], [@CR5], [@CR6]\]. The mechanism underlying resistance to standard chemotherapy has been studied but remains unknown. Nonetheless, novel drugs that target specific molecular pathways are being developed to improve the outcomes of chemotherapy-resistant ovarian cancer. Moreover, studies of chemotherapy-resistant ovarian cancer therapy indicate that effective treatments for CCC are available. However, clinical data relating directly to the treatment of CCC subtypes are limited.

Clinical trials have shown that in combination with chemotherapy, targeting vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), mammalian target of rapamycin (mTOR), EGFR, and poly (ADP-ribose) polymerase elicits positive results for EOC (Table [3](#Tab3){ref-type="table"}) \[[@CR52], [@CR61], [@CR71], [@CR78]--[@CR83]\]. However, limited data are available pertaining to novel therapies for either EOC or CCC, and further studies of novel treatment strategies are required to focus on the clinical features of CCC.Table 3Examples of targeted molecular cancer therapeutics for epithelial ovarian cancerCategoryTarget moleculeAgent(s)References*AngiogenesisVascular endothelial growth factorBevacizumab*\[[@CR71], [@CR85]\]FunctionBevacizumab is a humanized recombinant monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) receptor bindingEfficacyA clinical trial of bevacizumab addition to standard chemotherapy treatment in newly diagnosed advanced ovarian cancer demonstrated its efficacy. Bevacizumab monotherapy is effective in the treatment of persistent, resistant, or recurrent epithelial ovarian cancer (EOC). However, it remains unknown whether bevacizumab is effective for the clinical treatment of clear cell carcinoma (CCC). Some reports have suggested its efficacy in vitro and in vivo*Vascular endothelial growth factor receptorSorafenib*\[[@CR71]\]FunctionSorafenib is a multikinase inhibitor of intracellular Raf kinases and cell surface kinase receptors and thereby inhibits tumor growth and angiogenesisEfficacyPhase I and II studies show limited clincial benefits of sorafenib in the treatment of EOC, both as monotherapy and in combination with other drugs. No data is available regarding its use in the treatment of clear cell carcinoma (CCC). However, it is regarded as a useful therapy for patients with renal CCC. Therefore, sorafenib may be efficacious in the treatment of CCC*Vascular endothelial growth factor receptorPazopanib*\[[@CR71]\]FunctionPazopanib is a tyrosine kinase (multikinase) inhibitor that limits angiogensis and tumor growth by inhibiting cell surface vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors, and fibroblast growth factor receptorsEfficacyPazopanib monotherapy was relatively well tolerated, with similar toxicity to that of other small-molecule oral angiogenesis inhibitors. Promising single-agent activity was demonstrated in patients with recurrent ovarian cancer. Phase II and III trials indicate that pazopanib may have a role in the treatment of some women with EOC. No data demonstrates its efficacy in the treatment of CCC. However, pazopanib is regarded as useful in the treatment of renal CCC patients*Growth factorEpidermal growth factor receptorGefitinib, erlotinib, and lapatinib*\[[@CR78]\]FunctionGefitinib is a tyrosine kinase inhibitor that inhibits numerous tyrosine kinases that are associated with transmembrane cell surface receptors on both normal and cancer cells, including the epidermal growth factor receptor (EGFR) assoicated tyrosine kinaseEfficacyEGFR-targeted treatment had no effect when administered as monotherapy or as an adjunct to chemotherapy. However, EGFR-targeted treatment has shown promise in combination with other chemotherapeutic agents in clinical use. Further reports are expected. No data show the effects of targeting EGFR in CCC patients*Human epidermal growth factor receptor 2Trastuzumab*\[[@CR79]\]FunctionTrastuzumab is a monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER 2) and mediates antibody-dependent cellular cytotoxicity by inhibiting the proliferation of cells that overexpress the HER 2 proteinEfficacyHER-2 gene and protein overexpression have been reported in breast cancer and are associated with an aggressive clinical course and poor prognosis. A Gynecologic Oncology Group study demonstrated that HER 2 overexpression has no predictive or prognostic value in ovarian cancer. Although trastuzumab is not useful for ovarian cancer, no studies have investigated its use in the treatment of ovarian CCC. Further studies are needed to determine the efficacy of trastuzumab in the treatment of ovarian CCC*Insulin-like growth factor type I receptorAMG479*\[[@CR80]\]FunctionA complete human monoclonal antibody against insulin-like growth factor type I receptor (IGF-1R)EfficacyIGF-1R inhibition with ganitumab was well tolerated and demonstrated modest single-agent activity in unselected patients with platinum-sensitive recurrent ovarian cancer. To our knowledge, two clinical trails have been completed, although the results have nto yet been published. There are no data pertaining to its use in the treatment of CCCTumor Marker*Cancer antigen 125Oregovomab*\[[@CR71]\]FunctionOregovomab is a monoclonal antibody that binds to the antigen cancer antigen (CA 125)EfficacyA phase III clinical trial of intravenous oregovomab as post-chemotherapy consolidation has been conducted for EOC of tubal or peritoneal origin. Oregovomab monotherapy failed to improve outcomes after first line therapy. There are no data pertaining to its use in the treatment of CCC*Adhesionα5β1 integrinVolociximab*\[[@CR81]\]FunctionVolociximab binds to and inhibits the activity of α5β1 integrinEfficacyA phase II, multicenter, single arm, two stage study evaluated the efficacy, safety, and tolerability of weekly administration of volociximab as a single agent for the treatment of platinum-resistant, advanced EOC and primary peritoneal cancer. Volociximab was well tolerated, but there is insufficient evidence of its efficacy. There are no reports of volociximab treatments for CCC*SignalMammalian target of rapamycinTemsirolimus*\[[@CR82]\]FunctionThe mammalian target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate growth and homeostasis. Temsirolimus is an inhibitor of the mTOR pathwayEfficacyInhibitors of mTOR have shown therapeutic advantages when used in combination with other therapeutic modalities. Although clinical activity was low compared with the expected benefits, warranting further investigation. Existing data demonstrates the efficacy of targeting the mTOR pathway for CCC treatment in vitro and in vivo*SrcDasatinib*\[[@CR71]\]FunctionElevated activity of Src tyrosine kinase is suggested to be linked to cancer progression through the promotion of other signals. Dasatinib is a BCR-ABL tyrosine kinase inhibitor. It also inhibits the Src family, c-KIT, EPHA2, and platelet-derived growth factor receptor βEfficacyDasatinib has minimal activity as a single agent in patients with recurrent EOC. There are no data pertaining to its use in the treatment of CCC*c-KitImatinib*\[[@CR71]\]Functionc-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor, also known as "steel factor" or "c-kit ligand". Signaling through c-kit plays a role in cell survival, proliferation, and differentiationEfficacySome reports show dissapointing results in clinical outcomes. Few patients had sustained responses or stable disease, and treatment with imatinib did not prolong progression-free survival*DNA repairPoly ADP ribose polymeraseIniparib*\[[@CR83]\]FunctionProteins of the poly ADP ribose polymerase (PARP) family are involved in several cellular processes, mainly involving DNA repair and programmed cell death. Iniparib was originally believed to act as an irreversible inhibitor of PARP1EfficacyPhase II multicenter, single-arm clinical studies have been conducted to assess the efficacy and safety of carboplatin/gemcitabine in combination with iniparib in patients with platinum-sensitive or -resistant recurrent ovarian cancer. Phase III clinical trial of olaparib was initiated for patients with BRCA mutant ovarian cancer. However, low frequency of BRCA1/2 mutations in CCC were reported*ABL* Abelson murine leukemia, *BCR* breakpoint cluster region, *CA125* cancer antigen 125, *EGFR* epidermal growth factor receptor, *EPHA2* ephrin type-A receptor 2, *GFR* growth factor receptor, *HER2* human epidermal growth factor receptor 2, *IGF-1R* insulin like growth factor-1 receptor, *mTOR* mammalian target of rapamycin, *PARP* poly (ADP-ribose) polymerase, *PDGFR* platelet-derived growth factor receptor, *VEGF* vascular endothelial growth factor, *VEGFR* vascular endothelial growth factor receptor

### Targeting VEGF {#Sec6}

VEGF is an important therapeutic target in several solid tumors, including ovarian cancers, and the monoclonal antibody bevacizumab has been shown to bind to VEGF, inhibit receptor binding, and prevent the growth of tumor vasculature. Accordingly, the International Collaborative Ovarian Neoplasm Group (ICON7) and the Gynecologic Oncology Group (GOG) trials (GOG218) of bevacizumab addition to standard chemotherapy in newly diagnosed advanced ovarian cancer both reported significant improvements in PFS. The ICON7 trial specifically reported increased OS in a predefined group of patients with a high risk of disease progression \[[@CR84], [@CR85]\]. In addition, efficacy and safety of bevacizumab has been reported both in patients with platinum-sensitive and in those with platinum-resistant recurrent ovarian cancers \[[@CR84], [@CR85]\]. However, in these studies, histological subgroup analyses were not performed, and the clinical utility of VEGF as a therapeutic target for CCC has not been evaluated. Mabuchi et al. demonstrated the efficacy of bevacizumab in in vitro and in vivo CCC models, which showed that VEGF is frequently expressed and may be a promising therapeutic target for the management of CCC \[[@CR66]\]. However, a clinical trial has not been performed. Sunitinib is another possible therapeutic option for renal cell carcinoma treatment and acts as an oral, small-molecule, multitargeted receptor tyrosine kinase inhibitor (targeting VEGFR, platelet-derived growth factor receptor, and c-Kit). However, only a few small clinical studies have reported the efficacy of sunitinib for ovarian CCC \[[@CR86]\].

### Targeting the PI3K/AKT/mTOR signaling pathway {#Sec7}

PI3Ks are lipid kinases that regulate signaling pathways that are vital for neoplasia, including cell proliferation, adhesion, survival, and motility. The frequency of *PIK3CA* mutations in CCC has been estimated to be 40 %, and some studies suggest that the PI3K/AKT/mTOR pathway is a target with therapeutic potential \[[@CR53]\]. Moreover, immunohistochemical analyses have shown that mTOR is frequently activated in CCC (86.6 %) and that mTOR inhibition by RAD001 may be an effective treatment for CCC \[[@CR63]\]. Furthermore, Rahman et al. reported that *PIK3CA* mutations were associated with more favorable prognoses but did not predict the sensitivity of ovarian CCC cells to PI3K/AKT/mTOR inhibitors \[[@CR87]\]. Since more than 80 % of ovarian CCC shows activation of the AKT/mTOR pathway, it is of great interest to explore the potential of mTOR inhibitors \[[@CR88]\]. A very important GOG clinical trial is currently being conducted. The GOG-268 trial is an open-label phase II trial for newly diagnosed stage III and IV ovarian CCC to examine the activity of one of the mTOR inhibitors, temsirolimus. The primary endpoint of this trial is PFS at 12 months, and secondary endpoints include adverse events, duration of PFS and OS, and tumor response. IHC expression of components of the mTOR signaling pathway will be explored. Temsirolimus will be administered in combination with paclitaxel and carboplatin for six cycles. For the maintenance phase, temsirolimus will be administered on days 1, 8, and 15 every 3 weeks for 11 cycles. This clinical trial closed, and clinicians are awaiting the results with high expectations. Although targeting the PI3K/AKT/mTOR signaling pathway is promising, some problems remain, and there is no evidence of effective clinical management of CCCs, warranting further studies and clinical trials to prove the efficacy of PI3K/AKT/mTOR inhibition.

### Targeting AnxA4 {#Sec8}

AnxA4 is reportedly involved in exocytosis and regulation of epithelial Cl^−^ secretion \[[@CR20]\], and its overexpression in CCC has been shown to induce platinum resistance \[[@CR22]\]. Accordingly, IHC analyses of AnxA4 in CCC samples showed strong staining in 30 of 43 samples but moderate staining in the remaining 13 samples \[[@CR22]\].

Nonetheless, enhanced AnxA4 expression was recently shown to increase chemoresistance to carboplatin by contributing to extracellular efflux of the drug \[[@CR22]\]. Recently, we demonstrated molecular mechanisms underlying AnxA4-induced promotion of platinum drug efflux \[[@CR54]\]. Exposure of an AnxA4-overexpressing endometrial carcinoma cell line to platinum drugs caused relocalization of AnxA4 from the cytoplasm to the membrane fraction, and colocalization of P-type ATPase ATP7A (a copper and platinum transporter) to cell membranes. This colocalization promoted platinum drug efflux via ATP7A and induced the platinum resistance \[[@CR54]\].

Several studies have shown that AnxA4 induces drug resistance \[[@CR20]\], and suppression of AnxA4 expression improved platinum sensitivity of CCC in vitro and in vivo \[[@CR55]\]. In addition, Morimoto et al. showed that annexin repeat domains and calcium-binding sites of repeated annexin sequences are required for resistance to platinum-based drugs \[[@CR55]\]. The structure of AnxA4 and the mechanism of platinum resistance induced by AnxA4 is shown in Fig. [2](#Fig2){ref-type="fig"}. Taken together, these reports suggest the potential of AnxA4 targets for the treatment of ovarian CCC. However, no drugs have been shown to suppress AnxA4 expression. Nonetheless, in a study of the related annexin A2 (AnxA2) using chick chorioallantoic membrane assays, neutralizing antibodies significantly inhibited OV-90 cell motility and invasion in vitro and in vivo, suggesting the potential of AnxA2-neutralizing antibodies as therapeutic targets for AnxA2-overexpressing cancers \[[@CR89]\]. Similarly, AnxA4 blockade using neutralizing antibodies might limit the platinum resistance of CCC and is currently under investigation by our research group. Potentially, drugs that inhibit the function of AnxA4 in combination with platinum drugs may offer promising therapies for the treatment of CCC.Fig. 2The structure of annexin A4 (AnxA4) and related mechanisms of platinum resistance. **a** No treatment. AnxA4 is localized in the cytoplasm before exposure to platinum drugs. **b** After platinum drug exposure. Exposure to platinum drugs leads to AnxA4 relocalization from the cytoplasm to the cell membrane. AnxA4 has four annexin repeats that are packed into an α-helical disk within the C-terminal polypeptide core, which contains Ca^2+^-binding sites. These Ca^2+^-binding sites are involved in platinum resistance. **c** After platinum drug exposure. AnxA4 is attached to the membrane surface through bound Ca^2+^ ions and contributes to the efflux of platinum drugs via platinum transporters

### Targeting the *ARID1A* gene {#Sec9}

The AT-rich interactive domain 1A (SWI-like) gene (*ARID1A*) encodes BAF250A, which is a member of the SWI/SNF ATP-dependent chromatin remodeling complex. *ARID1A* plays an indispensable role in controlling gene expression and in tissue development and cellular differentiation \[[@CR70]\]. Moreover, CCCs reportedly have the highest frequency of *ARID1A* mutations (43--57 %) \[[@CR62]\].

Yamamoto et al. reported two critical associations between the AT-rich interactive domain-containing protein 1A (ARID1A) and CCC. In particular, deficiencies of ARID1A immunoreactions were evident at the stage of precursor lesions that lacked atypical cytology, indicating that the loss of ARID1A protein may occur as an early event in tumorigenesis. Moreover, loss of ARID1A protein expression is often coincident (not mutually exclusive) with *PIK3CA* mutation \[[@CR90]\]. However, a previous study demonstrated that inactivation of ARID1A alone is insufficient for tumor initiation, suggesting that additional genetic alterations are required to drive tumorigenesis \[[@CR91]\]. Chandler et al. also showed that the coexistent *ARID1A*-*PIK3CA* mutations promote ovarian clear cell tumorigenesis \[[@CR92]\]. Taken together, these studies suggest that ARID1A is related to CCC tumorigenesis, although the precise mechanisms remain unknown, and no drugs have yet been shown to target ARID1A. A recent study by Bitler et al. is an important study regarding the targeting of ARID1A for ovarian CCC \[[@CR93]\]. The study showed that *ARID1A* is mutated in over 50 % of ovarian CCCs and pharmacological inhibition of enhancer of zeste homolog 2 (EZH2) represents a novel treatment strategy for cancers involving *ARID1A* mutations. The study showed that EZH2 inhibitor selectively suppressed the growth of *ARID1A* mutated cells in vitro and in vivo via upregulating the expression of *PIK3IP1*, which negatively regulates PI3K/AKT signals. Further studies are expected to elucidate the detailed mechanisms of the cellular dysfunction caused by *ARID1A* mutations in CCCs and to expose the potential of ARID1A as a therapeutic target.

### Targeting hepatocyte nuclear factor-1β {#Sec10}

Hepatocyte nuclear factor-1β (HNF-1β) is a transcription activator that regulates the promoters and enhancers of genes expressed in the liver, digestive tract, pancreas, and kidneys \[[@CR64]\]. Recent studies have reported specific expression of HNF-1β in endometriosis and CCC and suggest that early differentiation into the clear cell lineage occurs in endometriosis \[[@CR64], [@CR74]\]. However, the role of HNF-1β expression in ovarian clear cell tumors and endometriosis remains uncertain. Nonetheless, RNA interference has been used to decrease HNF-1β expression and reportedly led to apoptotic cell death in CCC cell lines, indicating that HNF-1β expression may be tightly linked to CCC and that it could be essential for its survival \[[@CR74]\]. In addition, HNF-1β is reportedly expressed in almost all CCC cases \[[@CR64]\].

Accordingly, Kajihara et al. concluded that the HNF-1β-dependent pathway may provide novel insights into the regulation of glycogen synthesis, detoxification, and resistance to anticancer agents \[[@CR94]\]. In support of these conclusions, HNF-1β directly regulates multiple cancer-related genes, including those for dipeptidyl peptidase IV, osteopontin, tissue factor pathway inhibitor 2, AnxA4, and angiotensin-converting enzyme 2 \[[@CR74], [@CR94], [@CR95]\]. Genes that are upregulated in CCC are likely direct targets of HNF-1β. However, drugs that target HNF-1β have not been developed, warranting further studies of the mechanisms by which HNF-1β regulates various genes and its association with CCC.

### Targeting *ZNF217* {#Sec11}

The *ZNF217* gene on human 20q13.2 encodes a transcription factor that is overexpressed in 30 % of breast tumors and in several cell lines \[[@CR96]\]. Several studies show that overexpression of *ZNF217* in several cancers is associated with poor prognosis \[[@CR96], [@CR97]\]. Among these, Littlepage et al. reported that *ZNF217* overexpression promotes metastasis and resistance to chemotherapy and inhibits signaling events in vivo \[[@CR96]\]. These authors also showed that triciribine inhibits the growth of *ZNF217*-overexpressing cells in vitro and in vivo, indicating that it is a potential target for the treatment of *ZNF217*-overexpressing cancers.

In a previous study, *ZNF217* overexpression was reported in 20.0 % of CCC cases \[[@CR65]\]. Moreover, Rahman et al. showed that *ZNF217* gene overexpression is significantly correlated with lymph node metastasis in ovarian CCC. In comparison with small interfering RNA-treated cells without *ZNF217* overexpression, profound inhibition of cell migration and invasion was observed in cells overexpressing *ZNF217* \[[@CR98]\], suggesting that *ZNF217* is a potential therapeutic target for CCC.

Conclusion {#Sec12}
==========

As discussed above, the loss of *ARID1A* expression and/or PI3K activation is crucial for CCC tumorigenesis. Moreover, synergic effects of the loss of *ARID1A* expression and PI3K/AKT pathway activation and *ZNF217* overexpression may be related to ovarian CCC development \[[@CR99]\], warranting further studies of these associations and assessments of their potential as co-therapeutic targets for CCC.

CCC is highly resistant to current platinum-based treatment. However, if an AnxA4 blockade drug was developed, its use in combination with platinum drugs may have therapeutic activity against CCC.

AnxA2

:   annexin A2

AnxA4

:   annexin A4

ARID1A

:   AT-rich interactive domain-containing protein 1A

CCC

:   clear cell carcinoma

CPT-P

:   irinotecan plus cisplatin

EGFR

:   epidermal growth factor receptor

EOC

:   epithelial ovarian cancer

EZH2

:   enhancer of zeste homolog 2

GOG

:   Gynecologic Oncology Group

HER2

:   human epidermal growth factor receptor 2

HNF-1β

:   hepatocyte nuclear factor-1β

IHC

:   immunohistochemistry

mTOR

:   mammalian target of rapamycin

NER

:   nucleotide excision repair

OS

:   overall survival

PFS

:   progression-free survival

PI3K

:   phosphatidylinositol 3-kinases

SAC

:   serous adenocarcinoma

TC

:   paclitaxel plus carboplatin

VEGF

:   vascular endothelial growth factor
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